273 related articles for article (PubMed ID: 33363171)
1. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer.
Zhang Y; Lin A; Li Y; Ding W; Meng H; Luo P; Zhang J
Front Cell Dev Biol; 2020; 8():608969. PubMed ID: 33363171
[TBL] [Abstract][Full Text] [Related]
2. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
[TBL] [Abstract][Full Text] [Related]
3. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
4. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
6. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
7. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of the
Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
Front Immunol; 2021; 12():643282. PubMed ID: 34421886
[TBL] [Abstract][Full Text] [Related]
9. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
10. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
11. The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis.
Dong Y; Ye S; Li H; Li J; Liu R; Zhu Y
J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392565
[TBL] [Abstract][Full Text] [Related]
12. Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.
Miao XY; Wu H; Ye BC; Yi QW; Lin FN; Wang YL; Ren CL; Jiang YF; Li A
Sci Rep; 2022 Dec; 12(1):20734. PubMed ID: 36456601
[TBL] [Abstract][Full Text] [Related]
13. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
14. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
[TBL] [Abstract][Full Text] [Related]
15. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
16. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
17. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
Wang JY; Xiu J; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Oberley M; Spetzler D; Shen L; Korn WM; Lenz HJ
Ann Oncol; 2021 Jul; 32(7):906-916. PubMed ID: 33798656
[TBL] [Abstract][Full Text] [Related]
18. CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma.
Zhang Y; Chen K; Li L; Mao W; Shen D; Yao N; Zhang L
Ann Transl Med; 2021 Sep; 9(18):1443. PubMed ID: 34733995
[TBL] [Abstract][Full Text] [Related]
19.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
20. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
